163 related articles for article (PubMed ID: 29222311)
1. Role of the microenvironment across histological subtypes of NHL.
Tarte K
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):610-617. PubMed ID: 29222311
[TBL] [Abstract][Full Text] [Related]
2. Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.
Brauge B; Dessauge E; Creusat F; Tarte K
Front Immunol; 2023; 14():1288110. PubMed ID: 38022603
[TBL] [Abstract][Full Text] [Related]
3. Perivascular niches: critical hubs in cancer evolution.
Nowosad A; Marine JC; Karras P
Trends Cancer; 2023 Nov; 9(11):897-910. PubMed ID: 37453870
[TBL] [Abstract][Full Text] [Related]
4. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.
Rodriguez-Ruiz ME; Vitale I; Harrington KJ; Melero I; Galluzzi L
Nat Immunol; 2020 Feb; 21(2):120-134. PubMed ID: 31873291
[TBL] [Abstract][Full Text] [Related]
5. Generation of neighbor-labeling cells to study intercellular interactions in vivo.
Ombrato L; Nolan E; Passaro D; Kurelac I; Bridgeman VL; Waclawiczek A; Duarte D; Lo Celso C; Bonnet D; Malanchi I
Nat Protoc; 2021 Feb; 16(2):872-892. PubMed ID: 33311715
[TBL] [Abstract][Full Text] [Related]
6. Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis.
Xun Z; Ding X; Zhang Y; Zhang B; Lai S; Zou D; Zheng J; Chen G; Su B; Han L; Ye Y
Nat Commun; 2023 Feb; 14(1):933. PubMed ID: 36806082
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.
Ansell SM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):618-621. PubMed ID: 29222312
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.
Menter T; Tzankov A
Front Oncol; 2018; 8():54. PubMed ID: 29564225
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of primary
Greenawalt DM; Liang WS; Saif S; Johnson J; Todorov P; Dulak A; Enriquez D; Halperin R; Ahmed A; Saveliev V; Carpten J; Craig D; Barrett JC; Dougherty B; Zinda M; Fawell S; Dry JR; Byth K
Oncotarget; 2017 Nov; 8(59):99237-99244. PubMed ID: 29245897
[TBL] [Abstract][Full Text] [Related]
10. The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Kline J; Godfrey J; Ansell SM
Blood; 2020 Feb; 135(8):523-533. PubMed ID: 31790142
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Tumor Microenvironment of Leukemia and Lymphoma.
Höpken UE; Rehm A
Trends Cancer; 2019 Jun; 5(6):351-364. PubMed ID: 31208697
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment signaling driving lymphomagenesis.
Verdière L; Mourcin F; Tarte K
Curr Opin Hematol; 2018 Jul; 25(4):335-345. PubMed ID: 29746265
[TBL] [Abstract][Full Text] [Related]
13. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.
Tang X; Yang ZZ; Kim HJ; Anagnostou T; Yu Y; Wu X; Chen J; Krull JE; Wenzl K; Mondello P; Bhardwaj V; Wang J; Novak AJ; Ansell SM
Clin Cancer Res; 2022 Oct; 28(19):4322-4335. PubMed ID: 35686915
[TBL] [Abstract][Full Text] [Related]
14. Editorial: B Cell Non-Hodgkin's Lymphoma & Tumor Microenvironment Crosstalk: An Epigenetic Matter?
Denizot Y; Braza MS; Amin R
Front Genet; 2022; 13():912737. PubMed ID: 35664310
[No Abstract] [Full Text] [Related]
15. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Khurana A; Lin Y
Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
[TBL] [Abstract][Full Text] [Related]
16. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.
Gsottberger F; Brandl C; Wendland K; Petkovic S; Emmerich C; Erber R; Geppert C; Hartmann A; Mackensen A; Nitschke L; Müller F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638774
[TBL] [Abstract][Full Text] [Related]
17. The biology of the tumor microenvironment in DLBCL: Targeting the "don't eat me" signal.
Ennishi D
J Clin Exp Hematop; 2021 Dec; 61(4):210-215. PubMed ID: 34511583
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in the treatment of lymphoma.
Popovic LS; Matovina-Brko G; Popovic M; Popovic M; Cvetanovic A; Nikolic I; Kukic B; Petrovic D
World J Stem Cells; 2021 Jun; 13(6):503-520. PubMed ID: 34249225
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.
Ménard C; Rossille D; Dulong J; Nguyen TT; Papa I; Latour M; Bescher N; Bezier I; Chouteau M; Fest T; Houot R; Morschhauser F; Tarte K
Blood Adv; 2021 Apr; 5(8):2063-2074. PubMed ID: 33877296
[TBL] [Abstract][Full Text] [Related]
20. CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.
Bunse M; Pfeilschifter J; Bluhm J; Zschummel M; Joedicke JJ; Wirges A; Stark H; Kretschmer V; Chmielewski M; Uckert W; Abken H; Westermann J; Rehm A; Höpken UE
Nat Commun; 2021 Jan; 12(1):240. PubMed ID: 33431832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
